公开(公告)号：EP0799317B1

公开(公告)日：2004-04-28

申请号：EP95944594.1

申请日：1995-11-15

申请人： ZymoGenetics, Inc.

发明人： FOSTER, Donald, C. ,  HEIPEL, Mark, D. ,  HOLLY, Richard, D.

IPC分类号： C12N15/62 ,  C07K14/52 ,  C12N15/19 ,  C12N1/19 ,  C12N5/10 ,  C12N15/58

CPC分类号： C12N9/6459 ,  C07K14/524 ,  C07K2319/02 ,  C07K2319/036 ,  C07K2319/50 ,  C07K2319/75 ,  C12N15/625 ,  C12Y304/21069

摘要： DNA constructs useful in the production of thrombopoietin are disclosed. In general, the DNA constructs comprise a first DNA segment encoding a fusion of an amino-terminal secretory peptide joined to a thrombopoietin polypeptide and one or more additional DNA segments that provide for the transcription of the first segment. The secretory peptide is a native mammalian t-PA secretory peptide or may be modified to enhance proteolytic cleavage of the fusion. Also disclosed are cultured eukaryotic cells containing these DNA constructs and methods for producing thrombopoietin polypeptides through the use of the DNA constructs and cultured eukaryotic cells.

公开(公告)号：EP1237921A1

公开(公告)日：2002-09-11

申请号：EP00973811.3

申请日：2000-10-23

申请人： ZymoGenetics, Inc.

发明人： XU, Wenfeng ,  LOFTON-DAY, Catherine, E. ,  HENNE, Randall ,  PRESNELL, Scott, R. ,  YAO, Yue ,  NOVAK, Julia, E. ,  FOSTER, Donald, C. ,  YEE, David, P.

IPC分类号： C07K14/705 ,  C12N15/12 ,  C12N15/11 ,  C12N5/10 ,  C07K16/18 ,  C12Q1/68 ,  G01N33/53

CPC分类号： C07K14/7151

摘要： Novel secreted and membrane bound tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligands, agonists and antagonist. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate inflammation, tumor growth and metastasis, infection, immunity, and cellular maturation.

公开(公告)号：EP0874898A1

公开(公告)日：1998-11-04

申请号：EP96940607.0

申请日：1996-11-26

申请人： ZymoGenetics, Inc. ,  PPL Therapeutics

发明人： GARNER, Ian ,  COTTINGHAM, Ian ,  TEMPERLEY, Simon, M. ,  FOSTER, Donald, C. ,  SPRECHER, Cindy, A. ,  PRUNKARD, Donna, E.

IPC分类号： A01K67 ,  C12N9 ,  C12N15

摘要： Methods for producting protein C in transgenic non-human mammals are disclosed. The protein C is modified at the two-chain cleavage site between the light and heavy chains of protein C from Lys-Arg to R1-R2-R3-R4 where R1 through R4 are individually Arg or Lys. DNA segments encoding modified protein C are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing protein C expressed from the introduced DNA segments. The protein C expressed from the introduced DNA segments has anticoagulant activity when activated. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous protein C are also disclosed.

公开(公告)号：EP0506821B1

公开(公告)日：1998-02-04

申请号：EP91901991.9

申请日：1990-12-28

申请人： ZYMOGENETICS, INC.

发明人： FOSTER, Donald, C. ,  HOLLY, Richard, D.

IPC分类号： C12P21/02 ,  C12P15/00 ,  C12N9/64 ,  C07H15/12

CPC分类号： C12N9/6464 ,  C07K2319/00 ,  C12N9/60 ,  C12Y304/21069

摘要： Human protein C molecules are modified to provide increased resistance to inactivation by human plasma factors while retaining substantially the biological activity of human protein C. The modifications are generally to the heavy chain of protein C, which chain may be substituted with a protein C heavy chain of non-human origin, such as bovine, yielding a chimeric protein C molecule. The human protein C heavy chain may also be modified to be human-like, in that at least one amino acid from a non-human sequence may be substituted for the corresponding residue(s) of the human sequence, thereby allowing the molecule to retain substantially human characteristics yet having increased resistance to inactivation. Also included are methods for producing the modified protein C molecules and pharmaceutical compositions thereof. The modified molecules, having an increased half-life in human plasma, are particularly useful for treating coagulation-related disorders, such as protein C deficiency or thrombosis, or for promoting fibrinolysis in a patient.

公开(公告)号：EP0585356A1

公开(公告)日：1994-03-09

申请号：EP92912153.0

申请日：1992-05-14

申请人： ZYMOGENETICS, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON

发明人： LERNMARK, Ake ,  KARLSEN, Allen, E. ,  GRUBIN, Catherine, E. ,  HAGOPIAN, William ,  O'HARA, Patrick, J. ,  FOSTER, Donald, C.

IPC分类号： A61K38 ,  A61P37 ,  C07K16 ,  C12N1 ,  C12N9 ,  C12N15 ,  G01N33 ,  C12R1

CPC分类号： C12N9/88 ,  A61K38/00 ,  C07K16/40

摘要： La décarboxylase de l'acide glutamique (GAD) de cellules d'ilôts pancréatiques humains, un autoantigène impliqué dans l'évolution du diabète sucré insulino-dépendant (IDDM), a été clonée, séquencée, et exprimée par recombinaison. Des polypeptides recombinés de GAD de cellules d'ilôts humains et des anticorps spécifiques desdits polypeptides de GAD peuvent être utilisés dans des méthodes de diagnostic et de traitment, y compris dans la thérapie par immunoadsorption et dans l'induction de la tolérance immunitaire.

公开(公告)号：EP0506821A1

公开(公告)日：1992-10-07

申请号：EP91901991.0

申请日：1990-12-28

申请人： ZYMOGENETICS, INC.

发明人： FOSTER, Donald, C. ,  HOLLY, Richard, D.

IPC分类号： A61K38 ,  A61P7 ,  C07K14 ,  C07K19 ,  C12N5 ,  C12N9 ,  C12N15

CPC分类号： C12N9/6464 ,  C07K2319/00 ,  C12N9/60 ,  C12Y304/21069

摘要： On modifie des molécules de protéine C humaine afin d'obtenir une résistance accrue à l'inactivation par des facteurs de plasma humain, tout en conservant l'activité biologique de la protéine C humaine. Les modifications sont effectuées sur la chaîne lourde de la protéine C, laquelle chaîne peut être remplacée par une chaîne lourde de protéine C d'origine non humaine, par exemple d'origine ovine, produisant une molécule de protéine C chimérique. On peut également modifier la chaîne lourde de la protéine C humaine afin qu'elle ait une apparence humaine, de sorte qu'au moins un acide aminé tiré d'une séquence non humaine peut être remplacé par le/les reste(s) correspondant de la séquence humaine, ce qui permet à la molécule de conserver des caractéristiques humaines tout en ayant une résistance accrue à l'inactivation. L'invention concerne également des procédés de production des molécules de protéine C modifiées ainsi que leurs compositions pharmaceutiques. Les molécules modifiées présentant une demi-vie augmentée dans du plasma humain sont particulièrement utiles pour traiter les troubles relatifs à la coagulation, tels que les carences en protéine C ou la thrombose, ou afin de stimuler la fibrinolyse chez un patient.

公开(公告)号：EP1758610B1

公开(公告)日：2012-07-04

申请号：EP05756320.7

申请日：2005-05-20

申请人： ZymoGenetics, Inc.

发明人： KINDSVOGEL, Wayne, R. ,  HUGHES, Steven, D. ,  HOLLY, Richard, D. ,  CLEGG, Christopher, H. ,  FOSTER, Donald, C. ,  JOHNSON, Rebecca, A. ,  HEIPEL, Mark, D. ,  SIVAKUMAR, Pallavur, V.

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61K38/20

CPC分类号： C07K16/32 ,  A61K38/20 ,  A61K39/395 ,  A61K39/39558 ,  C07K16/2818 ,  C07K16/2896 ,  C07K2317/732 ,  A61K2300/00

摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.

公开(公告)号：EP1399472B1

公开(公告)日：2009-06-03

申请号：EP02713823.9

申请日：2002-03-07

申请人： ZymoGenetics, Inc.

发明人： CHANDRASEKHER, Yasmin, A. ,  NOVAK, Julia, E. ,  FOSTER, Donald, C. ,  XU, Wenfeng ,  JASPERS, Stephen, R.

IPC分类号： C07K14/00 ,  C07K14/715

CPC分类号： C07K14/7155 ,  C07K2319/00

摘要： A soluble receptor that binds to IL-20 having two polypeptide subunits, IL-22R and IL-20RB. The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.

公开(公告)号：EP1246846B1

公开(公告)日：2008-09-10

申请号：EP00986743.3

申请日：2000-12-22

申请人： ZymoGenetics, Inc.

发明人： FOSTER, Donald, C. ,  XU, Wenfeng ,  MADDEN, Karen, L. ,  KELLY, James, D. ,  SPRECHER, Cindy, A. ,  BRANDT, Cameron, S. ,  RIXON, Mark, W. ,  PRESNELL, Scott, R. ,  FOX, Brian, A.

IPC分类号： C07K14/715 ,  C12N15/62

CPC分类号： C07K14/7056 ,  A61K38/00 ,  C07K2319/00

摘要： A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.

公开(公告)号：EP0977861A1

公开(公告)日：2000-02-09

申请号：EP98918640.8

申请日：1998-04-23

申请人： ZymoGenetics, Inc.

发明人： PRESNELL, Scott, R. ,  GILBERT, Teresa ,  WHITMORE, Theodore, E. ,  FOSTER, Donald, C. ,  HART, Charles, E. ,  LEHNER, Joyce, M. ,  MARTINEZ, Theresa ,  HOFFMANN, Ross, C.

IPC分类号： C12N15/19 ,  C07K14/52 ,  C12N15/62 ,  C07K19/00 ,  C07K16/24 ,  C07K16/42 ,  C12Q1/66 ,  C12Q1/68 ,  G01N33/52 ,  G01N33/60

CPC分类号： C07K14/52 ,  C07K2319/00 ,  C07K2319/02

摘要： Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.